close

Advanced Esophageal Cancer Life Expectancy

Advanced Esophageal Cancer Life Expectancy
Advanced esophageal cancer life expectancy (Inoperable esophageal cancer and outcome of palliative care) - Patients with esophageal cancer have a weak prognosis. Due to the lack of large-scale screening methods, the diagnosis is usually performed at an advanced stage; Therefore, they have a short survival when they are diagnosed. The 5-year survival rate for patients with esophageal cancer < 20%. This is especially pronounced in some areas, such as north-eastern Iran, where the prevalence of esophageal cancer is high.

The esophageal cancer of five years has survived slightly increased over the last 20 years (5%-9%), but still low. Most patients present advanced, untreatable or metastatic disease. Advanced esophageal cancer life expectancy. At the time of diagnosis, 60% of patients were suitable for palliative therapy only. Recent progress in therapeutic endoscopy has allowed the growth of dysphagia and the quality of life. The endoscopic technique is chosen according to the characteristics of the tumor, because the diagnosis is often performed at an advanced stage, when the radical treatment is not feasible.

Dysphagia, or inability to swallow, is one of the most painful and debilitating symptoms in cancer patients related to esophageal obstruction. Advanced esophageal cancer life expectancy. Dysphagia causes a compromise on nutrition, pain and deterioration in quality of life. As the quality of life, and to some extent, the number of life remaining for these patients depends largely on their ability to swallow, the relief of dysphagia plays an important role in the development of this disease. Endoscopic endoscopy aims to restore swallowed replay, avoiding re-intervention and reducing hospitalization.

Advanced Esophageal Cancer Life Expectancy

Paliajul is an important objective of esophageal cancer therapy. The present administration choices for the dysphagia connection include: Esophageal widening, intraluminal stent, and Laser treatment: YAG, photodynamic treatment, argon laser, fundamental chemotherapy, outer radiotherapy, brachytherapy and chemoradiation treatment Combined. Clinical situations, local expertise and cost effectiveness play an important role in choosing appropriate treatment modalities. Treatment should ensure that most of these patients can avoid the fear of total dysphagia, regardless of the stent offered.

Palliative methods of treatment for cancer of the esophagus and heart include widening laser evaporation and other thermal methods, injecting alcohol, and introducing stents. Advanced esophageal cancer life expectancy. However, none of these procedures proved to be a simple, well-tolerated and sustainable method. The purpose of this study was to determine the recovery rate after two methods of authentication in patients with esophageal carcinoma which cannot be subjected to surgery in the province of Golestan, northeast Iran.

Thirty-nine cases met the inclusion criteria. The ratio between men and women is 1.6 to 1. The average age is 67.5 ± 13.7 years. Of these cases, 89.7% were randomized by the enlargement method and others (n = 3) with stenting. Most (92.3%) were diagnosed with SCC. The third part of the esophagus is the most numerous (51.3%). At the beginning of the study, 22 cases (56.4%) had a degree of three dysphagia (dysphagia at water) and the other 17 had dysphagia grade four or grade four. On the first track (one month after the procedure), seven cases were not available (died). They died between 6-31 D.

There was no significant association between the reduction of dysphagia and the methods of palliative care or the pathological types of esophageal cancer (P = 0.96). Patients ' age and recovery dysphagia were not significantly correlated (P = 0.238). Advanced esophageal cancer life expectancy. The average score of dysphagia increased significantly on the first track (3.37 vs 2.43, CI 95%, 0,62-1.25, P < 0.0001). Among the other 32 cases available on the first track, 25 were without dysphagia. Methods of survival analysis were used to estimate the length of dysphagia to reduce persistence after levels. The worsening of dysphagia is in any case considered a recurrence.

The average duration of persistent recovery is 172.1 D, and the median is 120 d. Of these 25 patients, in only ten cases the relapse of dysphagia was not reported until the end of the follow-up period. Advanced esophageal cancer life expectancy. At the end of the 6-month follow-up period, only 6 (15.4%) patients lived. The average time and mean survival rate were 137.6 D and 103 D after levels. In the restored group, the average time and survival was 177.1 D and 135 d after levels; While it is 60.7 D and 31 D in the other group; respectively. Kaplan-Meyer survival and Log-rank analyses were used to assess the relationship between the relief of dysphagia and the rate of survival of the cases and the significant differences reported.